Skip to content

Speakers

Expand/Collapse

Larry Brown
Executive Vice President & Chief Scientific Officer
Noveome Biotherapeutics, Inc.

Alison Mungenast
Principal Scientist & Neuroscience Lead
Eisai

Amy Easton
Senior Scientific Manager, Drug Discovery
Genentech

Aparna Vasanthakumar
Principal Research Scientist, Pharmacogenetics and Pharmacogenomics, Genomics Research Center/Chair of PPSP
AbbVie/ADNI

Day Two

Thursday 13th December 2018

9:15 am | Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

Bob Switzer
Founder, President & Chief Scientific Officer
Neuroscience Associates

Christian Schubert
Global Head, External Innovation
Servier

Day One

Thursday 13th December 2018

8:15 am | Neuroscience at the Inflection Point: Great News for Patients

David Donabedian
Chief Executive Officer
Axial Therapeutics

Eric Schaeffer
Senior Director, Neuroscience Innovation
Janssen

Day One

Thursday 13th December 2018

6:00 pm | Transforming Neurodegenerative Drug Development with State-ofthe-Art Technology

Henrik Zetterberg
Professor
University of Gothenburg

Day Two

Thursday 13th December 2018

8:45 am | Keynote Speaker: Reducing Undue Patient Burden with Development of Blood-Based Biomarkers – Goodbye Lumbar Puncture?

Ilaria Tassi
Lead Scientist
Alector

Ivana Rubino
Global Head of Medical Alzheimer’s
Biogen

James Gorman
Brain Targeting Program
Wyss Institute for Biologically Inspired Engineering, Harvard

Johan Luthman
Executive Vice President & Head of Research & Development
Lundbeck

John Renger
Chief Scientific Officer
Cerevel Therapeutics

Day One

Thursday 13th December 2018

9:15 am | Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

Jonathan Brotchie
Co-Founder, Director & President
Atuka Inc

Day One

Thursday 13th December 2018

8:45 am | The Evolving Landscape of Outsourcing Preclinical Research in Parkinson’s Disease: A CRO’s Perspective

Krystof Bankiewicz
President and CEO
Brain Neurotherapy Bio, Inc.

Lamya Shihabuddin
Head of Genetic Neurologic Diseases
Sanofi

Laszlo Kiss
Executive Director, WRD and Principal
Pfizer Ventures

Day Two

Thursday 13th December 2018

1:15 pm | Panel Discussion: Combining Expertise & Resources – Which Stakeholders are Essential for Successful Drug Development

Leslie Shinobu
Senior Director, Clinical Development
Biogen

Day Two

Thursday 13th December 2018

1:15 pm | Panel Discussion: Combining Expertise & Resources – Which Stakeholders are Essential for Successful Drug Development

12:45 pm | Patient-Centric Drug Development to Optimize Drug Development Efficiency

Michael Gold
Vice President, Neuroscience Development
AbbVie

Day One

Thursday 13th December 2018

5:30 pm | Don’t Enter the Clinic Without a Pilot Study

9:15 am | Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

Nahome Fisseha
Assistant Scientific Director, Neuroscience Clinical Development
AbbVie

Day Two

Thursday 13th December 2018

3:15 pm | Panel Discussion: Harnessing Optimism Towards Tackling Neurodegenerative Disease

2:45 pm | Demonstration of Early Target Engagement & Practical Implications for Drug Developers & Patients

Olivier Danos
Chief Scientific Officer
REGENXBIO

Pascal Sanchez
Director, Translational Sciences
Denali Therapeutics

Day Two

Thursday 13th December 2018

3:15 pm | Panel Discussion: Harnessing Optimism Towards Tackling Neurodegenerative Disease

Richard Hargreaves
Vice President, Head Neuroscience & Imaging Research & Early Development
Celgene

Day One

Thursday 13th December 2018

6:00 pm | Transforming Neurodegenerative Drug Development with State-ofthe-Art Technology

Richard Ransohoff
Venture Partner
Third Rock Ventures

Day One

Thursday 13th December 2018

9:15 am | Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

Ross Jeggo
Head of Neuroscience Research
Servier

Day One

Thursday 13th December 2018

7:00 pm | Chair’s Closing Remarks

6:00 pm | Transforming Neurodegenerative Drug Development with State-ofthe-Art Technology

9:15 am | Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

8:00 am | Chair’s Opening Remarks

Day Two

Thursday 13th December 2018

3:45 pm | Chair’s Closing Remarks

3:15 pm | Panel Discussion: Harnessing Optimism Towards Tackling Neurodegenerative Disease

1:15 pm | Panel Discussion: Combining Expertise & Resources – Which Stakeholders are Essential for Successful Drug Development

9:15 am | Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

8:30 am | Chair’s Opening Remarks

Samantha Hutten
Senior Associate Director, Research Partnerships
Michael J Fox

Day Two

Thursday 13th December 2018

9:15 am | Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

Sheraz Khan
Director of the Khan Lab
Harvard, MGH & MIT

Sid O’Bryant
Dr. Joe and Peggy Schooler Endowed Chair in Pharmacology & Neuroscience; Executive Director, Institute for Translational Research; Professor, Department of Pharmacology & Neuroscience
University of North Texas Health Science Center

Sophie Parmentier Batteur
Director, Neuroscience Discovery
Merck

Will Chen
Senior Director, Translational Biology
Biogen

Yaming Wang
Senior Research Scientist
Eli Lilly